Source BioScience PLC (LSE:SBS) - Share price - Overview

Stock Report

Source BioScience PLC SBS

Last Price
£-

Day Change
-|-%

As of -
- | GBP
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap63.02Mil
52-Wk Range-
Yield %-
ISINGB0009739649
Volume-
P/E-
P/S-
P/CF-

Share Price

Financials
201320142015
More ...
Income Statement
Revenue19.5325.1826.30
Operating Income-0.901.822.35
Net Income-1.760.931.47
Basic EPS-0.010.000.00
Avg. Diluted Shares Outstanding238320337
Balance Sheet
Current Assets9.988.5811.32
Non Current Assets31.0929.5937.09
Total Assets41.0838.1748.41
Current Liabilities9.267.489.41
Total Liabilities16.6812.7216.61
Total Equity24.4025.4531.80
Cash Flow
Operating Cash Flow2.122.374.11
Capital Expenditure-1.67-1.60-1.69
Free Cash Flow0.450.772.41

In millions, except "Basic EPS". Currency is GBP.

Company Profile

Source BioScience PLC is an international provider of the art laboratory services and products to the healthcare, life science research and biopharma industries.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Growth

Fiscal Year Ends

December

Employees

194
Key Stats
More ...
Price/Earning TTM-
Price/Book-
Price/Sales TTM-
Rev Growth (3 year avg)16.98
EPS Growth (3 year avg)-
Operating Margin % TTM8.92
Net Margin % TTM5.59
ROE TTM5.13
Debt/Equity0.19
Dividends
PreviousLatest
More ...
Declared Date19/09/9712/08/98
Ex-Div24/11/9721/09/98
Paid09/01/98t.b.c.
Amnt1.601.82
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.